Stockscreener 앱 받기
21.48
0.19%
0.08
전일 마감가:
$21.40
열려 있는:
$21.42
하루 거래량:
15,892
Relative Volume:
0.07
시가총액:
$772.60M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.51%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$21.16
$21.68
1주일 범위
$20.88
$23.27
52주 변동 폭
$18.69
$32.75
Ceribell Inc Stock (CBLL) Company Profile
명칭
Ceribell Inc
전화
(800) 436-0826
주소
360 N. PASTORIA AVENUE, SUNNYVALE
CBLL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
21.41 | 772.60M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
126.16 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.81 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.55 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.06 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.58 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-05 | 개시 | BofA Securities | Buy |
| 2024-11-05 | 개시 | Canaccord Genuity | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
Ceribell Inc 주식(CBLL)의 최신 뉴스
CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Analysts - Defense World
Rhumbline Advisers Makes New Investment in CeriBell (NASDAQ:CBLL) - Defense World
CeriBell’s Earnings Call: Strong Growth Amid Challenges - TipRanks
William Blair Estimates CeriBell’s Q1 Earnings (NASDAQ:CBLL) - Defense World
Canaccord Genuity Group Reaffirms Buy Rating for CeriBell (NASDAQ:CBLL) - Defense World
Ceribell revenue increases 41% to USD 18.5M in Q4 2024 - Medical Buyer
CeriBell, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Ceribell, Inc.: Strong Financial Performance and Strategic Investments Justify Buy Rating - TipRanks
Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating for Ceribell, Inc. - TipRanks
Ceribell, Inc. Reports Strong 2024 Financial Growth - TipRanks
Ceribell, Inc.: Strong Financial Performance and Growth Potential Drive Buy Rating - TipRanks
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth - Investing.com
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth By Investing.com - Investing.com UK
CeriBell Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ceribell, Inc. Reports Significant Revenue Growth in Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
CeriBell Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL) - Seeking Alpha
CeriBell (CBLL) to Release Earnings on Tuesday - MarketBeat
Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference - GlobeNewswire
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Target Price from Analysts - MarketBeat
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Price Target from Brokerages - Defense World
Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
CeriBell, Inc. to Announce Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
CeriBell (CBLL) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Hospitals adopt AI tech to improve seizure detection in Humboldt County - KRCR
Nexalin Technology (NASDAQ:NXL) vs. CeriBell (NASDAQ:CBLL) Head-To-Head Contrast - Defense World
CeriBell (NASDAQ:CBLL) Trading 9.1% HigherShould You Buy? - MarketBeat
Beta Bionics targets up to $616 mln valuation in US IPO - Reuters
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) Price Target at $32.60 - MarketBeat
Ceribell Expands its Executive Management Team by Two - MPO-mag
CeriBell (NASDAQ:CBLL) Hits New 52-Week LowTime to Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Shares Down 9.2%Should You Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Trading Down 3.3%What's Next? - MarketBeat
Contrasting CeriBell (NASDAQ:CBLL) & Cutera (NASDAQ:CUTR) - Defense World
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus PT from Analysts - Defense World
Head to Head Contrast: CeriBell (NASDAQ:CBLL) & Vaso (OTCMKTS:VASO) - Defense World
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - Marketscreener.com
CeriBell (NASDAQ:CBLL) Shares Down 2.6%Here's Why - MarketBeat
CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ceribell CEO to Present at J.P. Morgan Healthcare Conference 2025: Medical Tech Innovation in Focus - StockTitan
Ceribell Inc (CBLL) 재무 분석
Ceribell Inc (CBLL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Ceribell Inc 주식 (CBLL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TPG GP A, LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
380,268 |
6,464,556 |
3,967,422 |
| Tammenoms Bakker Juliet | Director |
Oct 15 '24 |
Buy |
17.00 |
237,234 |
4,032,978 |
2,475,110 |
0.57%
0.83%
자본화:
|
볼륨(24시간):